Safety and Effectiveness of Nitroprusside in Preventing No-Reflow During Percutaneous Coronary Intervention: A Systematic Review

Cell Biochemistry and Biophysics

Volumn 68, Issue 1, 2014, Pages 201-206

  Su, Qiang ^a   Li, Lang ^a   Naing, Kyaw Aung ^a   Sun, Yuhan ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Nitroprusside; No reflow; Percutaneous coronary intervention; Randomized controlled trial; Systematic review

Indexed keywords

NITROPRUSSIDE SODIUM; VASODILATOR AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); FACTUAL DATABASE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; SEVERITY OF ILLNESS INDEX;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; MYOCARDIAL INFARCTION; NITROPRUSSIDE; PERCUTANEOUS CORONARY INTERVENTION; SEVERITY OF ILLNESS INDEX; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84891603338     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9690-9     Document Type: Article

References (18)

1. Keeley, E. C., Boura, J. A., & Grines, C. L. (2003). Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet, 361, 13-20.
2. Kloner, R. A., Ganote, C. E., & Jennings, R. B. (1974). The no-reflow phenomenon after temporary coronary occlusion in the dog. Journal of Clinical Investigation, 54, 1496-1508.
3. Kelly, R. V., Cohen, M. G., & Stouffer, G. A. (2005). Incidence and management of "no-reflow" following percutaneous coronary interventions. American Journal of the Medical Sciences, 329, 78-85.
4. Akdemir, R., Karakurt, O., Kilic, H., et al. (2010). Effect of reperfusion therapy on index of myocardial performance in acute myocardial infarction: Thrombolytics versus primary angioplasty. Heart and Vessels, 25, 87-91.
5. Bates, J. N., Baker, M. T., Guerra, R, Jr, & Harrison, D. G. (1991). Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochemical Pharmacology, 42(Suppl), S157-S165.
6. Pan, W., Wang, L. F., Yu, J. H., et al. (2009). Intracoronary nitroprusside in the prevention of the no-reflow phenomenon in acute myocardial infarction. Chinese Medical Journal, 122, 2718-2723.
7. Hendler, A., Aronovich, A., Kaluski, E., et al. (2006). Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIMI 3 flow. Journal of Invasive Cardiology, 18, 32-36.
8. Amit, G., Cafri, C., Yaroslavtsev, S., et al. (2006). Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. American Heart Journal, 152, 887. e9-887. e14.
9. Sakamoto, H., Shimamoto, S., Kawase, Y., Ueda, H., Murakami, T., & Tamura, T. (2010). Effect of nitroprusside on reducing infarct size after primary percutaneous coronary intervention for acute myocardial infarction. Journal of the American College of Cardiology, 55, A104. E968.
10. Valero, S. J., Moreno, R., Reyes, R. M., et al. (2008). Pharmacological approach of no-reflow phenomenon related with percutaneous coronary interventions. Cardiovascular and Hematological Agents in Medicinal Chemistry, 6, 125-129.
11. Gibson, C. M., & Schomig, A. (2004). Coronary and myocardial angiography: Angiographic assessment of both epicardial and myocardial perfusion. Circulation, 109, 3096-3105.
12. Tesic, M. B., Stankovic, G., Vukcevic, V., & Ostojic, M. C. (2010). The use of intracoronary sodium nitroprusside to treat no-reflow after primary percutaneous coronary intervention in acute myocardial infarction. Herz, 35, 114-118.
13. Airoldi, F., Briguori, C., Cianflone, D., et al. (2007). Frequency of slow coronary flow following successful stent implantation and effect of nitroprusside. American Journal of Cardiology, 99, 916-920.
14. Pasceri, V., Pristipino, C., Pelliccia, F., et al. (2005). Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. American Journal of Cardiology, 95, 1358-1361.
15. Kiernan, T. J., Ruggiero, N. J, I. I., Bernal, J. M., et al. (2009). The no-reflow phenomenon in the coronary circulation. Cardiovascular and Hematological Agents in Medicinal Chemistry, 7, 181-192.
16. Kitakaze, M., Asakura, M., Kim, J., et al. (2007). Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomised trials. Lancet, 370, 1483-1493.
17. Marzilli, M., Orsini, E., Marraccini, P., & Testa, R. (2000). Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation, 101, 2154-2159.
18. Ross, A. M., Gibbons, R. J., Stone, G. W., Kloner, R. A., & Alexander, R. W. (2005). A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). Journal of the American College of Cardiology, 45, 1775-1780.